Overview

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

Status:
Withdrawn

Trial end date:
2020-08-21

Target enrollment:

Participant gender:

Summary

This is a placebo-controlled clinical trial to assess the utility of Guanfacine Extended Release (GXR) in the management of patients with Prader Willi Syndrome (PWS) who have significant aggression or self-injury. The purpose of this trial is to establish the safety of GXR with a specific focus on metabolic effects.

Phase:

Phase 4

Details

Lead Sponsor:

NYU Langone Health

Collaborator:

Winthrop University Hospital

Treatments:

Guanfacine